Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722148 · ClinicalTrials.gov registry record · NA
Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT02722148 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants.
The verdict
NCT02722148, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a prospective single center clinical trial of allergen-specific immune signature-guided dietary elimination therapy to assess the clinical effectiveness of this technique.
Interventions
- DEVICE Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-04-21 |
| Est. Completion | 2018-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722148
The ClinicalTrials.gov registry entry for NCT02722148 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy is the first listed.
NCT02722148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02722148 about?
NCT02722148 is a clinical study titled "Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)". This is a prospective single center clinical trial of allergen-specific immune signature-guided dietary elimination therapy to assess the clinical effectiveness of this technique.
What is the current status of trial NCT02722148?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2016-04-21. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02722148?
The interventions under investigation include: Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy (DEVICE).
Who is sponsoring clinical trial NCT02722148?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.